Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)
Innovent claims two PhIII wins for PCSK9 antibody, but non-China strategy remains unclear
Much of the spotlight on Chinese biotech and Eli Lilly partner Innovent has focused on its anti-PD-1 efforts, but on Thursday the company touted a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
